[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"poag\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:poag":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100639811","direct-selective-laser-trabeculoplasty-dslt-for-patients-with-glaucoma-or-ocular-hypertension-previously-treated-with-slt-100639811",false,"NCT07589270","Direct Selective Laser Trabeculoplasty (DSLT) for Patients With Glaucoma or Ocular Hypertension Previously Treated With SLT","Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Ocular Hypertension or Open-Angle Glaucoma Patients Previously Treated With Selective Laser Trabeculoplasty (SLT)","Inclusion Criteria:\n\n* • Adult patients (18-80 years old), scheduled to undergo DSLT treatment in one eye.\n\n  * Diagnosis of ocular hypertension (OHTN) or primary open angle glaucoma (POAG).\n  * Previous history of selective laser trabeculoplasty (SLT) treatment. • Medication free or washed out IOP at time 0 ranging from ≥ 18 through 32 mm Hg.\n\nExclusion Criteria:\n\n* • Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0)\n\n  * Previous glaucoma surgeries\u002Finterventions:\n\n    * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).\n    * Recent SLT failures (within 6 months of initial treatment).\n  * Patients who have undergone cataract surgery within the prior 2 years.\n  * Secondary glaucoma:\n\n    o Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.\n  * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study looks at a new laser treatment for people with high eye pressure or a type of glaucoma called open-angle glaucoma. All patients in the study have already had a similar laser treatment before (called SLT). In this study, everyone will receive the same treatment, called Direct Selective Laser Trabeculoplasty (Voyager™ DSLT). This device is approved by the FDA and will be used as directed. The goal is to understand how safe it is and how well it works in these patients.\n\nGlaucoma is a major cause of permanent vision loss. A common treatment, called SLT, uses a laser to help lower pressure inside the eye. The newer treatment, DSLT, works in a similar way but does not touch the eye, which may make it quicker and more comfortable. DSLT has worked well in patients who have never had laser treatment before, but there is not much information about how well it works in people who have already had SLT.\n\nThe main goal of this study is to see how much the treatment lowers eye pressure after 6 months, compared to before treatment. To get accurate results, patients will stop their usual glaucoma eye drops for a short time before their eye pressure is measured. This helps show the true effect of the laser treatment.\n\nThe study will also look at other outcomes. These include how much eye pressure drops in percentage terms, how many patients have successful results, and whether patients can reduce the number of glaucoma medications they use. It will also track if any patients need additional glaucoma treatments later.",[27,28],"Ocular Hypertension Glaucoma","POAG","NOT_YET_RECRUITING","2026-05-13",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":21},"2026-04",{"date":37,"type":21},"2027-03",{"name":39,"class":40},"The New York Eye Surgery Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":41},"100569231","long-term-safety-and-efficacy-of-a-modified-suprachoroidal-silicone-tube-sst-shunt-100569231","NCT06691555","Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt","The Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt in Patients with Primary Open-angle Glaucoma (POAG) and Pseudo-exfoliative Glaucoma (PXG) Over an Extended Follow-up Period","Inclusion Criteria:\n\n* Previously were treated with Suprachoroidal silicone tube shunt\n* Willing and able to participate in this cross sectional observational follow up\n* Participant capable of giving informed consent\n\nExclusion Criteria:\n\n* Condition that could impact the ability of the participant to attend a follow-up visit as per the discretion of the investigator","40 Years","90 Years",{"count":52,"type":21},66,"OBSERVATIONAL","The goal of this observational study is to evaluate the long-term safety and efficacy of a modified suprachoroidal silicone tube (SST) shunt in treating patients with primary open-angle glaucoma (POAG) and pseudo-exfoliative glaucoma (PXG).\n\nThe main questions it aims to answer are:\n\nDoes the SST shunt maintain intraocular pressure (IOP) reduction over an extended follow-up period? What is the effect of the SST shunt on endothelial cell count (ECC) and overall corneal health?\n\nParticipants will:\n\nUndergo intraocular pressure (IOP) measurements Have their endothelial cell count (ECC) evaluated Complete assessments of best corrected visual acuity (BCVA) Be assessed for C\u002FD ratio Be monitored for adverse events or shunt-related complications over time",[56,57,28,58,59,60],"Glaucoma","Open Angle Glaucoma (OAG)","Ocular Hypertension","Exfoliation Syndrome","Choroidal Effusions",[62,63,56,64,65,66,67],"MIGS","Suprachoroidal Space","Open-Angle Glaucoma","Suprachoroidal Silicone Tube","Suprachoroidal Shunt","Glaucoma Shunt","RECRUITING","2024-11-14",{"date":71,"type":33},"2024-11-15",{"date":73,"type":33},"2024-11-08",{"date":75,"type":21},"2024-11-30",{"name":77,"class":40},"Davinci LTD"]